

# UCB – QuickView

25 January 2013

## Investment summary: Wherefore art thou romo

Much attention rests on UCB's three recently launched drugs but forthcoming news regarding its Phase III, Amgen-partnered antibody, romosozumab, could help to maintain the current share price momentum. Phase II data show a rapid increase in bone mineral density (BMD) in women with post-menopausal osteoporosis (PMO) that is superior to existing therapies, with no concerning safety signals. Data from the ongoing Phase III trials assessing c 10,000 women with PMO are not expected until 2015. However, new fracture healing data, expected in H1 13 and Phase III trial initiations, expected this year could provide further indication of its potential.

### Better efficacy over competitors...

Top-line Phase II data show a rapid increase in BMD over 12 months at the lumbar spine and hip of women with PMO treated with the anti-sclerostin antibody, romosozumab, that is significantly superior to alendronate (Fosamax) or teriparatide (Forteo). In a meta-analysis, 12 month BMD increases at the lumbar spine compared favourably to increases with 36 month denosumab (Prolia) and zoledronic acid (Reclast) treatment (11.3% vs 8.8% and 6.7% respectively), and 24 month odanacatib treatment (2.3%), Merck's Phase III bone resorption inhibitor.

### ...with no significant safety signals

Anti-resorptive agents, largely bisphosphonates (eg Fosamax), dominate the c \$8bn global osteoporosis market. However, their prolonged use has been associated with osteonecrosis of the jaw, severe pain and hypocalcaemia. The only FDA-approved bone-builder, Forteo, carries a black box warning against osteosarcoma. So far, the only significant side effect associated with romosozumab is mild injection site reactions, although further studies will assess longer term safety risks including the possibility of abnormal bone formation seen in patients naturally lacking sclerostin.

### New Phase III trials to highlight potential

Data from the current Phase III trial is not expected until 2015. However, new data and new Phase III trials should support the anti-sclerostin approach. Positive data on two Phase II romosozumab studies in tibial and hip fracture healing could trigger the start of Phase III trial(s) in this indication this year. Eli Lilly's direct competitor, blosozumab, at least 12 months behind, could start major Phase III trials this year in PMO, and data from Phase II with this antibody could also be presented.

### Valuation: Romosozumab newsflow should buoy shares

UCB shares have risen c 37% in the last year, largely because of rising expectations for three new products: Cimzia, Vimpat and Neupro. UCB now trades on a one year forward P/E of 24x, a 72% premium to its peer group. However, we believe that 2013 romosozumab related newsflow still represents important catalysts for the shares.

#### Consensus estimates

Year end	Revenue (€m)	PBT (€m)	EPS (€)	Net debt (€m)	P/E (x)	Yield (%)
12/10	2,786	19	1.54	1,511	27.9	2.2
12/11	2,876	229	1.49	1,550	28.8	2.3
12/12e	3,218	292	1.62	1,499	26.5	2.9
12/13e	3,325	356	1.82	1,392	23.6	2.4

Source: Bloomberg.

Price €42.9  
Market cap €7,868m

#### Share price graph



#### Share details

Code UCB  
Listing Brussels  
Sector Pharma & biotech  
Shares in issue 183.4m

#### Business

UCB is a Belgium biopharmaceutical company focused on neurology and immunology. Rebuilt via sale of its chemical business and acquisitions of Schwarz Pharma and Celltech, UCB is now in growth-phase propelled by lead products Cimzia, Vimpat and Neupro. Its late-stage pipeline is high-risk/high-reward.

#### Bull

- Cimzia line extensions, Neupro and Vimpat success lift CVN guidance.
- Keppra generic erosion is lower than consensus forecasts.
- Positive anti-sclerostin data and trial progress.

#### Bear

- Pfizer's oral Xeljanz will compete ahead of injectable anti-TNFs in RA.
- Clinical risk associated with late-stage pipeline.
- Gearing limits M&A opportunities.

#### Analysts

Luke Poloniecki +44 (0)20 3077 5700  
Robin Davison +44 (0)20 3077 5737

[healthcare@edisoninvestmentresearch.co.uk](mailto:healthcare@edisoninvestmentresearch.co.uk)

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

#### EDISON INVESTMENT RESEARCH LIMITED

Edison Investment Research Limited (Edison) is a leading international investment research company. Edison and its subsidiaries (Edison Group) have won industry recognition, with awards both in Europe and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison's research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York, Sydney and Wellington. Edison is authorised and regulated by the United Kingdom's Financial Services Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only.

#### DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c)(1)(a), (b) and (c) of the FAA). It is not intended for retail clients. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct an investment business and, accordingly, does not hold any positions in the securities mentioned in this report. However, their respective directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication.

Registered in England, number 4794244, Edison Investment Research Limited is authorised and regulated by the United Kingdom Financial Services Authority.

[www.edisoninvestmentresearch.co.uk](http://www.edisoninvestmentresearch.co.uk). Registered on the New Zealand Financial Service Providers Register, number 247505, Edison Investment Research (NZ) Limited is registered to provide wholesale and/or generic financial adviser services and is regulated by the New Zealand Financial Markets Authority.

**London** +44 (0)20 3077 5700

Lincoln House, 296-302 High Holborn  
London, WC1V 7JH, UK

**New York** +1 646 653 7026

245 Park Avenue, 24th Floor  
NY 10167, New York, US

**Wellington** + 64 4894 8555

Level 15 HP Tower, 171 Featherston St  
Wellington 6011, NZ

**Sydney** +61 (0)2 9258 1162

Level 33, Australia Square, 264 George St,  
Sydney, NSW 2000, Australia